New pancreatic cancer combo trial halted early
NCT ID NCT06199466
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 23 times
Summary
This early-phase trial tested whether adding the experimental drug YL-13027 to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe for people with advanced pancreatic cancer that had stopped responding to previous treatment. Only 4 participants were enrolled before the study was terminated. The main goal was to find the safest dose and see if the combination could shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.